Cytokinetics vs Gossamer Bio
CYTK and GOSS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYTK and GOSS compare
Gossamer Bio is the larger company, worth 647 times as much as Cytokinetics ($5.1B against $7.8M).
Gossamer Bio grew revenue faster over the last twelve months (32.4% versus −21.1% for Cytokinetics).
Gossamer Bio keeps more of each dollar of sales as profit, with a net margin of −235% compared with −1321% at Cytokinetics.
Cytokinetics scores higher on the StockData Score (4 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYTK | GOSS |
|---|---|---|
| Size and price | ||
| Market cap | $7.8M | $5.1B |
| Share price | $62.99 | $10.38 |
| Change, 1 year | 1.6% | −94.6% |
| Change, 5 years | 53.3% | −99.0% |
| Beta (5Y) | 0.82 | 1.58 |
| Employees | 673 | 161 |
| StockData Score | ||
| Total score | 4 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.1× (better) | 95.2× |
| FCF yield | −7408% | −3.2% (better) |
| Growth | ||
| Revenue growth (TTM) | −21.1% | 32.4% (better) |
| Revenue growth, 5Y average | 9.5% | – |
| Profitability | ||
| Operating margin | −1046% | −312% (better) |
| Net margin | −1321% | −235% (better) |
| FCF margin | −858% | −305% (better) |
| Financial health | ||
| Interest coverage | – | −15.2× |
| Current ratio | 6.66 (better) | 0.53 |
| Altman Z-score | −3.37 (better) | −16.39 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 115% | 0.98% |
| Held by insiders | 0.68% | 2.8% |
| Insider net buying, 12 months | −$50.6M | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 14.0% | 0.26% |
Go deeper
- CYTK stock overview
- CYTK income statement
- CYTK valuation and score
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.